2.11
-0.14(-6.22%)
Currency In USD
Address
490 Arsenal Way
Watertown, MA 02472
United States of America
Phone
617 231 0700
Sector
Healthcare
Industry
Biotechnology
Employees
110
First IPO Date
October 02, 2020
| Name | Title | Pay | Year Born |
| Mr. Andrew J. Hirsch M.B.A. | Chief Executive Officer, President & Director | 1.08M | 1971 |
| Dr. Kenneth C. Anderson M.D., Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board | 45,000 | 1951 |
| Ms. Jolie M. Siegel J.D. | Chief Legal Officer & Corporate Secretary | 610,400 | 1977 |
| Ms. Kendra Adams | Chief Financial Officer & Treasurer | 711,215 | N/A |
| Dr. Leonard M. J. Reyno M.D. | Chief Medical Officer | 837,480 | 1962 |
| Ms. Courtney Solberg | Senior Manager of Investor Relations | 0 | N/A |
| Mr. Mark Mossler | Chief Accounting Officer | 0 | 1974 |
| Dr. Nathanael S. Gray Ph.D. | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Ms. Kelly A. Schick | Chief People Officer | 0 | 1980 |
| Ms. Paige Mahaney Ph.D. | Chief Scientific Officer | 0 | N/A |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.